Introduction
============

Patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are at high risk for invasive fungal infection (IFI) when presented with prolonged neutropenia after induction chemotherapy.[@b1-ceor-10-371] IFI is associated with increased morbidity and mortality and is a serious concern in AML, MDS, and other immunocompromised patients, such as those undergoing hematopoietic stem-cell transplantation (HSCT) or with graft-vs-host disease (GVHD).[@b2-ceor-10-371],[@b3-ceor-10-371] Several professional guidelines recommend using antifungal prophylaxis in high-risk patients and consider timely initiation of antifungal use as a critical component in improving patient outcomes.[@b4-ceor-10-371]--[@b6-ceor-10-371]

To date, many antifungal drugs have demonstrated poor efficacy, particularly in the prevention of invasive aspergillosis. The use of fluconazole as prophylaxis is limited by its narrower spectrum of antifungal activity, being effective only against *Candida* strains.[@b7-ceor-10-371] Voriconazole does not show any significantly greater benefit than other azoles in antifungal prophylaxis.[@b8-ceor-10-371]--[@b10-ceor-10-371] When given in capsules, itraconazole is absorbed poorly, and when given as oral suspension it has gastrointestinal side effects.[@b11-ceor-10-371] Micafungin and caspofungin can only be administered intravenously, are approved only for prophylaxis of *Candida* infections, and the effectiveness of prophylaxis in hematological patients has not been consistently reported.[@b12-ceor-10-371]--[@b15-ceor-10-371] Finally, unless there are contraindications to use of azole antifungals, amphotericin is not recommended for use as the primary prophylactic treatment.[@b16-ceor-10-371]

Posaconazole is a new-generation azole that is recommended for use in neutropenic patients, SCT recipients, and patients with severe GVHD for antifungal prophylaxis by National Comprehensive Cancer Network, American Society of Clinical Oncology, and Infectious Diseases Society of America guidelines.[@b5-ceor-10-371],[@b7-ceor-10-371],[@b17-ceor-10-371] Three formulations of posaconazole -- oral suspension, delayed-release tablet, and parenteral -- are currently US Food and Drug Administration (FDA)-approved for the prophylaxis of invasive *Aspergillus* and/or *Candida* infections. In clinical trials, posaconazole has proved to be clinically superior to other triazoles in preventing IFI, especially aspergillosis.[@b17-ceor-10-371],[@b18-ceor-10-371] Implementation of clinical guidelines and research findings in current practice, however, has not been well followed. Further, real-world evidence leveraging nationwide, geographically representative data to assess associations between posaconazole use and patient outcomes is lacking.

This study set out to describe real-world use of different formulations of posaconazole in a hospital setting. Four cohorts of patients at high risk of IFI -- those with AML, MDS, HSCT, and GVHD -- and those without diagnosis codes for FI during the index hospitalization were identified as likely candidates for antifungal prophylaxis. Within each cohort, the observed antifungal use was identified and categorized as single (posaconazole or other antifungal), multiple (antifungals with and without posaconazole), or none. Selected economic and clinical outcomes are described for each of the cohorts.

Methods
=======

Study design
------------

A retrospective observational study using the Premier Health-care Database (PHD) was conducted to describe real-world use of posaconazole in a hospital setting and among patients at high risk of FIs, as well as to explore use of common antifungal drugs and occurrence of IFIs up to 90 days after discharge.

Data source
-----------

The PHD is a large database of geographically diverse US hospitals containing patient- and hospital-level information and representing a variety of payer types. The PHD contains a subset of data from the Premier Quality Advisor platform that offers deidentified, Health Insurance Portability and Accountability Act-compliant data. Use of the PHD data for this study was considered exempt from institutional review-board oversight, as dictated by Title 45 Code of Federal Regulations (CFR), Part 46 of the US, specifically 45 CFR 46.101(b)(4) (<http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.html>). In addition, in accordance with the Health Insurance Portability and Accountability Act privacy rule, data disclosed from the PHD are considered deidentified as per 45 CFR 164.506(d)(2)(ii)(B) through the "expert determination" method.

During the study period, data from standard hospital-discharge files, including patient demographics, disease states, admission and discharge diagnoses, patient disposition, and discharge status were available from more than 654 million stays, representing more than 20% of all US hospital discharges. At the time of analyses, there were more than 151 million patients. The PHD also contains a date-stamped log of billed items, including procedures, devices, medications, laboratory tests, and diagnostic and therapeutic services at the individual patient level. Drug-utilization information is available by day of stay and includes quantity, dose, strength, and hospital cost. Patients can be tracked across inpatient and hospital-based outpatient settings, as well as across visits with a unique identifier within a single hospital. Hospital information included geographic location, population served (urban vs rural), teaching status, and number of beds.

Study population
----------------

All patients discharged from an inpatient hospital visit between January 1, 2007 and March 31, 2016 receiving at least one dose of posaconazole, whether used alone or in combination with other antifungals, were identified using medication-billing records in the PHD. The formulation used (oral suspension, oral tablet, parenteral) was also identified from the billing records. Since the tablet formulation of posaconazole was approved by the FDA in November 2013 and the parenteral formulation approved in March 2014, any posaconazole used prior to November 2013 was labeled as the oral suspension. If the formulation after November 2013 could not be determined from the billing record, it was classified as an unknown formulation. Trends in use by formulation or use of combinations of posaconazole formulations were displayed over time.

AML patients that did not achieve remission or were in relapse and patients with MDS, HSCT, or GVHD were identified as high-risk population for IFIs and included in the study. For descriptions of antifungal-medication use in the study cohort, all patients discharged from an inpatient hospital visit between January 1, 2007 and March 31, 2016 with a primary diagnosis code for each condition were identified. A hierarchical approach was used to categorize patients into one of the four groups. All patients with a primary ICD9/10 diagnosis code for AML (205.00, 205.02, C92.00, C92.40, C92.50, C92.02, C92.42, or C92.52) who did not meet the criteria for HSCT were categorized into the AML cohort. All patients with a primary ICD9/10 diagnosis code for MDS (238.72-75, D46.0-2, D46.9 or D46.A-C) who did not meet the criteria for HSCT were categorized into the MDS cohort. Patients with a primary ICD9/10 procedure code for HSCT ([Table S1](#SD1-ceor-10-371){ref-type="supplementary-material"}) who did not meet the criteria for the GVHD cohort were categorized into the HSCT cohort. Patients with a primary or secondary ICD9/10 diagnosis code for GVHD (279.50-3 or D89.810-3) who also had at least one dose of a selected immunosuppressant drug (methylprednisolone, prednisone, beclomethasone, cyclosporine, sirolimus, tacrolimus, mycophenolate mofetil, thalidomide, methotrexate, azathioprine, pentostatin, infliximab, rituximab, etanercept, methoxsalen, denileukin, antithymocyte globulin, daclizumab, basiliximab, or alemtuzumab) on the hospital medication-billing record were categorized into the GVHD cohort.

For each cohort, the first qualifying visit was identified as the index visit. Patients were then excluded if they had an admission or discharge diagnosis code for an FI during the index visit (ICD9 diagnosis codes 112.XX, 114.X, 115.XX, 116.X, 117.X, 118, 348.89, 484.6, 484.7, 495.4, and 495.6; ICD10 diagnosis codes B36.8, B37.X-B49, H16.069, J67.4, and J67.6). Subsequent inpatient and outpatient encounters in the same hospital system were identified through 90 days after the index visit discharge date.

Antifungal-use groups of interest
---------------------------------

Within each high-risk cohort, patients were further categorized into one of antifungal-use groups based upon the use of antifungal medications during the index visit: single antifungal (posaconazole) -- the only antifungal used during the index visit was posaconazolesingle antifungal (not posaconazole) -- use of only one of fluconazole, itraconazole, voriconazole, micafungin, caspofungin, or amphotericin B during the index visitmultiple antifungals (including posaconazole) -- multiple antifungal drugs listed above were used during index encounter, including posaconazolemultiple antifungals (not including posaconazole) -- multiple antifungal drugs used during the index visit, but none were posaconazoleno antifungal -- no antifungal drugs were used during the index visit

Patient and hospital characteristics
------------------------------------

Selected patient and visit characteristics (age, sex, race, ethnicity, admission type, and discharge status) were obtained from the PHD and are presented by high-risk cohort and antifungal-treatment groups. Selected hospital characteristics (teaching status, urban/rural location, US Census geographical regions, and number of beds) were similarly obtained and are presented in the same manner.

Study outcomes
--------------

Outcomes of interest during the index hospitalization and following discharge from the index hospitalization were determined. Outcomes during index hospitalization were total hospital length of stay (LOS) and total hospital cost. Outcomes following index hospital discharge were the occurrence of 30-, 60-, and 90-day readmissions and subsequent outpatient visits with the presence of a primary or secondary ICD admission or discharge diagnosis code for IFI ([Table S2](#SD2-ceor-10-371){ref-type="supplementary-material"}).

Statistical analysis
--------------------

Descriptive statistics were derived. Continuous data are expressed as means ± SD, minimum and maximum, and medians and IQR. Categorical data are expressed as counts and percentages. Patients with missing values for total hospital cost were excluded from cost analysis. Patients who died during the index encounter were excluded from the denominator for analyses of subsequent encounters.

Results
=======

Posaconazole use in a hospital setting
--------------------------------------

Prior to 2013, the only formulation of posaconazole available in the US was the oral suspension. The number of patients receiving posaconazole oral suspension peaked in 2012 and rapidly declined thereafter ([Figure 1](#f1-ceor-10-371){ref-type="fig"}). Much of that decline may have resulted from availability of the oral tablet formulation, which demonstrated rapid growth in use in 2014 and 2015. The proportion of inpatients receiving posaconazole who were administered the tablet formulation increased from 24.8% in 2014 to 62.3% in the first quarter of 2016 (data not shown), while the proportion of inpatients receiving the oral suspension decreased from 67.5% to 32.7% during this same period (data not shown). There was less use of the most recently marketed formulation: parenteral posaconazole. When used, it was frequently prescribed in combination with other formulations during the same hospitalization.

Patient and hospital characteristics of high-risk patients
----------------------------------------------------------

[Table 1](#t1-ceor-10-371){ref-type="table"} presents patient and hospital characteristics for each of the four patient cohorts. [Table S3](#SD3-ceor-10-371){ref-type="supplementary-material"} presents patient and hospital characteristics by patient cohort for the five antifungal categories. A total of 51,648 patients who met study criteria were categorized: 19,872 (38%) AML patients, 12,125 (23%) MDS patients, 14,220 (28%) HSCT patients, and 5,431 (11%) GVHD patients ([Table 1](#t1-ceor-10-371){ref-type="table"}). Among these, 58% of AML patients (11,482), 94% of MDS patients (11,382), 33% of HSCT patients (4,736), and 37% of GVHD patients (2,014) did not receive any of the selected antifungal medications during the index hospitalization ([Table S3](#SD3-ceor-10-371){ref-type="supplementary-material"}). Posaconazole, alone or in combination with another drug, was received in \<10% of patients across the four cohorts.

The median patient age was highest in the MDS cohort (median 79 years, IQR 70--85 years) and lowest in the GVHD cohort (median 52 years, IQR 35--61 years). In each cohort, there was a higher proportion of men than women; however, in the subgroup of MDS patients receiving posaconazole plus other antifungals, only 41% were male. Across all four cohorts, approximately 70% of patients were white. Approximately 70%--85% of patients with AML, MDS, or GVHD had an emergent or urgent visit, while only 36% of patients with HSCT had an emergent or urgent visit. Most patients were discharged home, and there were more AML patients transferred to another hospital, hospice, or expired than other cohorts. Consistently across the four cohorts, it appeared that patients receiving posaconazole as the only antifungal during the index encounter had low in-hospital mortality among the five antifungal groups.

More than half of HSCT and GVHD patients were admitted to hospitals with 550+ beds, while fewer patients with AML (37%) or MDS (24%) were treated at such hospitals. With regard to geographical distribution, more patients with HSCT (30%) and GVHD (26%) were treated at hospitals in the Northeast than patients with AML (18%) or MDS (20%). [Table S3](#SD3-ceor-10-371){ref-type="supplementary-material"} shows that patients treated with antifungals were more frequently seen in hospitals with 550+ beds than hospitals of smaller sizes. Posaconazole, alone or in combination with another antifungal, was found to be more frequently used in AML, MDS, and GVHD patients in the Northeast and in hospitals with 550+ beds, which is consistent with the fact that Northeast hospitals tend to have larger bed capacity than other regions in our study sample (data not shown).

The majority of patients with HSCT (73%) or GVHD (64%) were treated at teaching hospitals, whereas only around half of or fewer patients with AML (52%) or MDS (42%) were treated at teaching hospitals. Across all cohorts and treatment categories ([Table S3](#SD3-ceor-10-371){ref-type="supplementary-material"}), over 90% of patients were admitted to a hospital in an urban area. Overall, antifungal prophylaxis was more frequently given to all four cohorts by teaching hospitals. In both single and multiple antifungal therapies, posaconazole was more frequently given to AML and MDS patients by teaching hospitals.

Economic and clinical outcomes of high-risk patients
----------------------------------------------------

[Tables 2](#t2-ceor-10-371){ref-type="table"}[](#t3-ceor-10-371){ref-type="table"}[](#t4-ceor-10-371){ref-type="table"}--[5](#t5-ceor-10-371){ref-type="table"} present economic and clinical outcomes by antifungal categories for AML, MDS, HSCT, and GVHD cohorts, respectively. Across these four cohorts, patients with no antifungal treatment were found to have the shortest LOS, whereas patients with more than one type of antifungal had the longest LOS. There was not a noticeable difference in LOS between patients treated with posaconazole only and patients treated with one other antifungal only or between patients receiving multiple antifungals treated with and without posaconazole. Consistently, in all four cohorts, patients with no antifungal treatment had the lowest total hospital cost, whereas patients with more than one type of antifungal had the highest. Total hospital costs were similar between patients treated with single antifungals whether posaconazole or other agent; and between patients receiving multiple antifungals whether with or without posaconazole.

IFI-related readmissions and subsequent outpatient visits were rare events. [Figure 2](#f2-ceor-10-371){ref-type="fig"} shows that the percentage of patients with subsequent inpatient and outpatient encounters with IFI at 90 days post-index encounter fluctuated yet remained very low over the study period. For each cohort, there was not a noticeable difference across different years. Patients with no antifungal treatment had the fewest IFI-related readmissions and subsequent outpatient visits, and no remarkable differences were found among the remaining four treatment groups ([Tables 2](#t2-ceor-10-371){ref-type="table"}[](#t3-ceor-10-371){ref-type="table"}[](#t4-ceor-10-371){ref-type="table"}--[5](#t5-ceor-10-371){ref-type="table"}).

Discussion
==========

Antifungal prophylaxis for high-risk patients has been promoted by various scientific societies due to the rising incidence of life-threatening IFIs and undesired outcomes when initiation of antifungal use is delayed.[@b19-ceor-10-371] This is one of the first studies to observe and characterize the possible use of antifungal prophylaxis and associated outcomes in a large, representative database. Our findings indicate that across different cohorts of immunocompromised patients, antifungal prophylaxis appears to be underutilized, especially in patients with shorter hospital stays. As patient LOS extended, a greater proportion of the at-risk population started to receive multiple antifungal drugs, even when no FI was present. Although antifungal prophylaxis is currently regarded as the gold standard in situations with a high risk of FI, such as in these immunocompromised patients,[@b4-ceor-10-371],[@b5-ceor-10-371],[@b7-ceor-10-371],[@b9-ceor-10-371] it is possible that the clinician's perspective of risk for an individual patient may vary and/or there may be inconsistency in the interpretation and application of guideline recommendations for antifungal prophylaxis.[@b20-ceor-10-371]

The unexpected finding that a substantial number of high-risk patients did not receive antifungal prophylaxis highlights the need for initiatives to promote the adoption of guideline recommendations. The higher proportion of patients receiving antifungal prophylaxis within teaching hospitals may indicate greater knowledge, receptivity, and/or availability of tools for utilization of antifungal prophylaxis or could be due to the fact that teaching hospitals may contain a higher proportion of complex patients considered at extremely high risk of FIs. Regional differences may also indicate varying degrees of knowledge, receptivity, and available resources. Additional investigations may facilitate a better understanding of clinician decision-making and guide development of tools for greater use of antifungal prophylaxis in appropriate patients across all hospitals in the nation.

There are a number of limitations to this study. First, the identification of antifungals was based on text-string searching in hospitals' charge masters. Since hospitals record their pharmacy costs in a variety of ways, some discharges that used an antifungal of interest may not have been captured. Second, due to the retrospective nature of this study and lack of access to medical records, it was extremely difficult to differentiate antifungal prophylaxis from treatment or empirical treatment. One important assumption of the study was that patients with antifungal use who did not have any diagnosis for an FI were likely receiving the antifungal(s) for prophylaxis. Under this assumption, those who received antifungal prophylaxis in the beginning of their stay but later developed an FI were not a focus of this study, and addition of this subset of patients in future studies could lead to different conclusions. Third, the risk of IFI and corresponding therapeutic strategies to address IFI were not constant during all the phases of treatment of the four cohorts. For example, since induction chemotherapy is the first time that a patient experiences profound immunosuppression, most AML patients are at greater risk of IFI at this stage, but differentiations of the treatment stage of each patient were not included in this study. Fourth, patients discharged from January 1, 2007 to March 30, 2007 may have had a hospitalization during the 90 days prior to their index hospitalization, raising a possibility, albeit small, that some readmissions might be misclassified. It is also important to note that this US study may not be generalizable to other health-care settings. Lastly, the current study design was descriptive. No unadjusted or adjusted comparisons were made.

Conclusion
==========

To date, there has been limited retrospective research using a large, all-payer, geographically representative hospital database to describe high-risk patients who require antifungal prophylaxis. This current study, despite its limitations, adds real-world knowledge to this field. The results revealed that contrary to guideline recommendations, some high-risk patients did not receive any antifungal prophylaxis. Additional research is necessary to confirm this finding and determine reasons for potential underutilization of antifungal prophylaxis in high-risk patients, in order to develop interventions and tools to improve guideline adherence and clinical outcomes.

Supplementary material
======================

###### 

Primary ICD9/10 procedure code for hematopoietic stem-cell transplantation

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ICD9: 41.0X
  ICD10: 30230AZ, 30230G0, 30230G1, 30230X0, 30230X1, 30230Y0, 30230Y1, 30233AZ, 30233G0, 30233G1, 30233X0, 30233X1, 30233Y0, 30233Y1, 30240AZ, 30240G0, 30240G1, 30240X0, 30240X1, 30240Y0, 30240Y1, 30243AZ, 30243G0, 30243G1, 30243X0, 30243X1, 30243Y0, 30243Y1, 30250G0, 30250G1, 30250X0, 30250X1, 30250Y0, 30250Y1, 30253G0, 30253G1, 30253X0, 30253X1, 30253Y0, 30253Y1, 30260G0, 30260G1, 30260X0, 30260X1, 30260Y0, 30260Y1, 30263G0, 30263G1, 30263X0, 30263X1, 30263Y0, 30263Y1, 3E03005, 3E03305, 3E04005, 3E04305, 3E05005, 3E05305, 3E06005, or 3E06305
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Primary or secondary ICD admission or discharge diagnosis code for invasive fungal infection

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ICD9: 112.2, 112.4, 112.5, 112.81, 112.83, 112.84, 112.85, 112.89, 112.9, 114, 114.1, 114.2, 114.3, 114.4, 114.5, 114.9, 115, 115.01, 115.02, 115.03, 115.04, 115.05, 115.09, 115.11, 115.12, 115.13, 115.14, 115.15, 115.19, 115.91, 115.92, 115.93, 115.94, 115.95, 115.99, 116, 116.1, 117.1, 117.2, 117.3, 117.5, 117.6, 117.7, 117.8, 117.9, 118, 348.89, 484.6, 484.7, 495.4 or 495.6
  ICD-10: B37.1, B37.41, B37.49, B37.5, B37.6, B37.7, B37.81, B37.82, B37.89, B37.9, B38.0, B38.1, B38.2, B38.4, B38.7, B38.81, B38.89, B38.9, B39.0, B39.1, B39.2, B39.3, B39.4, B39.5, B39.9, B40.0, B40.1, B40.2, B40.7, B40.81, B40.89, B40.9, B41.0, B41.7, B41.8, B41.9, B42.0, B42.1, B42.7, B42.81, B42.89, B42.9, B43.1, B43.2, B43.8, B43.9, B44.0, B44.1, B44.7, B44.81, B44.89, B44.9, B45.0, B45.1, B45.3, B45.7, B45.8, B45.9, B46.0, B46.1, B46.2, B46.4, B46.5, B46.8, B46.9, B47.0, B47.1, B48.2, B48.3, B48.4, B48.8, B49, G93.89, H16.069, J67.4 or J67.6
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Patient, visit, and hospital characteristics by antifungal use

  AML                                                Single antifungal (posaconazole)   Single antifungal (not posaconazole)   Multiple antifungals (including posaconazole)   Multiple antifungals (not including posaconazole)   No antifungal                                      
  ------------------------- ------------------------ ---------------------------------- -------------------------------------- ----------------------------------------------- --------------------------------------------------- --------------- -------- ------- -------- -------- -------
  **Unique patients**                                565                                                                       4,778                                                                                               812                      2,235            11,482   
  **Unique providers**                               103                                                                       516                                                                                                 112                      309              724      
  **Age, years**            Minimum--                0                                  85+                                    0                                               85+                                                 5               85+      0       85+      0        85+
  maximum                                                                                                                                                                                                                                                                             
  Mean                      57                                                          58                                                                                     56                                                                  54               69                
  SD                        ±16.35                                                      ±19.88                                                                                 ±15.52                                                              ±18.33           ±17.72            
  Median                    60                                                          63                                                                                     59                                                                  58               73                
  IQR                       47                       69                                 48                                     73                                              45                                                  68              44       67      61       81       
  **Age-group, years**      0--17                    9                                  1.6%                                   246                                             5.1%                                                4               0.5%     118     5.3%     185      1.6%
  18--34                    51                       9.0%                               397                                    8.3%                                            91                                                  11.2%           243      10.9%   535      4.7%     
  35--44                    66                       11.7%                              373                                    7.8%                                            96                                                  11.8%           208      9.3%    510      4.4%     
  45--64                    231                      40.9%                              1,571                                  32.9%                                           353                                                 43.5%           940      42.1%   2,254    19.6%    
  65--74                    134                      23.7%                              1,189                                  24.9%                                           195                                                 24.0%           531      23.8%   2,721    23.7%    
  75+                       74                       13.1%                              1,002                                  21.0%                                           73                                                  9.0%            195      8.7%    5,277    46.0%    
  **Sex**                   Male                     334                                59.1%                                  2,662                                           55.7%                                               398             49.0%    1,191   53.3%    6,337    55.2%
  Female                    231                      40.9%                              2,115                                  44.3%                                           414                                                 51.0%           1,042    46.6%   5,143    44.8%    
  Unknown                   0                        0                                  1                                      0                                               0                                                   0               2        0.1%    2        0        
  **Race**                  White                    398                                70.4%                                  3,327                                           69.6%                                               600             73.9%    1,517   67.9%    8,367    72.9%
  Black                     46                       8.1%                               469                                    9.8%                                            77                                                  9.5%            237      10.6%   1,088    9.5%     
  Other                     121                      21.4%                              982                                    20.6%                                           135                                                 16.6%           481      21.5%   2,027    17.7%    
  **Ethnicity**             Not Hispanic or Latino   310                                54.9%                                  2,139                                           44.8%                                               459             56.5%    1,036   46.4%    5,379    46.8%
  Hispanic or Latino        52                       9.2%                               348                                    7.3%                                            56                                                  6.9%            159      7.1%    619      5.4%     
  Other                     203                      35.9%                              2,291                                  47.9%                                           297                                                 36.6%           1,040    46.5%   5,484    47.8%    
  **Admission type**        Urgent/emergent          464                                82.1%                                  3,896                                           81.5%                                               639             78.7%    1,840   82.3%    9,926    86.4%
  Elective                  91                       16.1%                              847                                    17.7%                                           151                                                 18.6%           375      16.8%   1,449    12.6%    
  Trauma                    0                        0                                  13                                     0.3%                                            1                                                   0.1%            8        0.4%    30       0.3%     
  Other/unknown             10                       1.8%                               22                                     0.5%                                            21                                                  2.6%            12       0.5%    77       0.7%     
  **Discharge status**      Home                     440                                77.9%                                  3,093                                           64.7%                                               592             72.9%    1,480   66.2%    4,606    40.1%
  Transferred               19                       3.4%                               356                                    7.5%                                            28                                                  3.4%            105      4.7%    1,979    17.2%    
  SNF                       15                       2.7%                               166                                    3.5%                                            27                                                  3.3%            75       3.4%    594      5.2%     
  Expired                   51                       9.0%                               691                                    14.5%                                           119                                                 14.7%           412      18.4%   1,961    17.1%    
  Hospice                   31                       5.5%                               393                                    8.2%                                            33                                                  4.1%            138      6.2%    2,025    17.6%    
  Other/unknown             9                        1.6%                               79                                     1.7%                                            13                                                  1.6%            25       1.1%    317      2.8%     
  **No. of beds**           1--149                   2                                  0.4%                                   140                                             2.9%                                                1               0.1%     29      1.3%     885      7.7%
  150--249                  7                        1.2%                               492                                    10.3%                                           37                                                  4.6%            229      10.2%   1,601    13.9%    
  250--349                  60                       10.6%                              625                                    13.1%                                           104                                                 12.8%           220      9.8%    1,960    17.1%    
  350--449                  119                      21.1%                              661                                    13.8%                                           134                                                 16.5%           255      11.4%   2,203    19.2%    
  450--549                  34                       6.0%                               738                                    15.4%                                           36                                                  4.4%            324      14.5%   1,615    14.1%    
  550+                      343                      60.7%                              2,122                                  44.4%                                           500                                                 61.6%           1,178    52.7%   3,218    28.0%    
  **Geographic region**     West                     44                                 7.7%                                   807                                             16.9%                                               53              6.5%     338     15.1%    2,046    17.8%
  Midwest                   55                       9.8%                               737                                    15.5%                                           87                                                  10.7%           372      16.7%   2,330    20.3%    
  Northeast                 183                      32.4%                              817                                    17.1%                                           196                                                 24.1%           405      18.2%   2,115    18.4%    
  South                     283                      50.1%                              2417                                   50.7%                                           476                                                 58.7%           1120     50.2%   4,991    43.5%    
  **Teaching**              Yes                      156                                27.6%                                  2,133                                           44.6%                                               187             23.0%    819     36.6%    6,110    53.2%
  No                        409                      72.4%                              2,645                                  55.4%                                           625                                                 77.0%           1,416    63.4%   5,372    46.8%    
  **Urban/rural**           Rural                    6                                  1.1%                                   244                                             5.1%                                                11              1.4%     82      3.7%     1,007    8.8%
  Urban                     559                      98.9%                              4,534                                  94.9%                                           801                                                 98.6%           2,153    96.3%   10,475   91.2%    
  **MDS**                                                                                                                                                                                                                                                                             
  **Unique patients**                                29                                                                        624                                                                                                 17                       73               11,382   
  **Unique providers**                               19                                                                        300                                                                                                 10                       56               748      
  **Age, years**            Minimum--maximum         20                                 85                                     0                                               85+                                                 6               81       1       85+      0        85+
  Mean                      62                                                          68                                                                                     57                                                                  65               77                
  SD                        ±15.31                                                      ±14.99                                                                                 ±19.28                                                              ±13.64           ±12.36            
  Median                    68                                                          71                                                                                     62                                                                  66               79                
  IQR                       53                       73                                 61                                     79                                              51                                                  68              58       73      71       86       
  **Age-group, years**      0--17                    0                                  0                                      5                                               0.8%                                                1               5.9%     1       1.4%     39       0.3%
  18--34                    2                        6.9%                               22                                     3.5%                                            1                                                   5.9%            1        1.4%    63       0.6%     
  35--44                    2                        6.9%                               13                                     2.1%                                            0                                                   0               2        2.7%    101      0.9%     
  45--64                    8                        27.6%                              162                                    26.0%                                           9                                                   52.9%           29       39.7%   1,368    12.0%    
  65--74                    13                       44.8%                              172                                    27.6%                                           3                                                   17.6%           23       31.5%   2,431    21.4%    
  75+                       4                        13.8%                              250                                    40.1%                                           3                                                   17.6%           17       23.3%   7,380    64.8%    
  **Sex**                   Male                     21                                 72.4%                                  377                                             60.4%                                               7               41.2%    36      49.3%    6,187    54.4%
  Female                    8                        27.6%                              246                                    39.4%                                           10                                                  58.8%           37       50.7%   5,194    45.6%    
  Unknown                   0                        0                                  1                                      0.2%                                            0                                                   0               0        0       1        0        
  **Race**                  White                    18                                 62.1%                                  453                                             72.6%                                               12              70.6%    54      74.0%    8,401    73.8%
  Black                     5                        17.2%                              57                                     9.1%                                            2                                                   11.8%           7        9.6%    1,050    9.2%     
  Other                     6                        20.7%                              114                                    18.3%                                           3                                                   17.6%           12       16.4%   1,931    17.0%    
  **Ethnicity**             Not Hispanic or          17                                 58.6%                                  295                                             47.3%                                               11              64.7%    41      56.2%    5,441    47.8%
  Latino                                                                                                                                                                                                                                                                              
  Hispanic or Latino        3                        10.3%                              44                                     7.1%                                            1                                                   5.9%            2        2.7%    612      5.4%     
  Other                     9                        31.0%                              285                                    45.7%                                           5                                                   29.4%           30       41.1%   5,329    46.8%    
  **Admission type**        Urgent/emergent          18                                 62.1%                                  510                                             81.7%                                               13              76.5%    58      79.4%    9,857    86.6%
  Elective                  11                       37.9%                              109                                    17.5%                                           4                                                   23.5%           14       19.2%   1,434    12.6%    
  Trauma                    0                        0                                  1                                      0.2%                                            0                                                   0               1        1.4%    21       0.2%     
  Other/unknown             0                        0                                  4                                      0.6%                                            0                                                   0               0        0       70       0.6%     
  **Discharge status**      Home                     25                                 86.2%                                  399                                             63.9%                                               14              82.4%    28      38.4%    7,775    68.3%
  Transferred               0                        0                                  25                                     4.0%                                            1                                                   5.9%            8        11.0%   301      2.6%     
  SNF                       0                        0                                  70                                     11.2%                                           1                                                   5.9%            8        11.0%   1,996    17.5%    
  Expired                   2                        6.9%                               64                                     10.3%                                           0                                                   0               18       24.7%   457      4.0%     
  Hospice                   1                        3.4%                               57                                     9.1%                                            1                                                   5.9%            11       15.1%   744      6.5%     
  Other/unknown             1                        3.4%                               9                                      1.4%                                            0                                                   0               0        0       109      1.0%     
  **No. of beds**           1--149                   0                                  0                                      32                                              5.1%                                                0               0        2       2.7%     1,053    9.3%
  150--249                  1                        3.4%                               85                                     13.6%                                           1                                                   5.9%            9        12.3%   1,846    16.2%    
  250--349                  4                        13.8%                              112                                    17.9%                                           1                                                   5.9%            8        11.0%   2,187    19.2%    
  350--449                  4                        13.8%                              99                                     15.9%                                           3                                                   17.6%           10       13.7%   2,097    18.4%    
  450--549                  1                        3.4%                               103                                    16.5%                                           1                                                   5.9%            16       21.9%   1,564    13.7%    
  550+                      19                       65.5%                              193                                    30.9%                                           11                                                  64.7%           28       38.4%   2,635    23.2%    
  **Geographic region**     West                     3                                  10.3%                                  94                                              15.1%                                               1               5.9%     10      13.7%    1,813    15.9%
  Midwest                   2                        6.9%                               75                                     12.0%                                           2                                                   11.8%           9        12.3%   2,192    19.3%    
  Northeast                 10                       34.5%                              110                                    17.6%                                           4                                                   23.5%           12       16.4%   2,289    20.1%    
  South                     14                       48.2%                              345                                    55.3%                                           10                                                  58.9%           42       57.6%   5,088    44.7%    
  **Teaching**              Yes                      9                                  31.0%                                  338                                             54.2%                                               3               17.6%    30      41.1%    6,557    57.6%
  No                        20                       69.0%                              286                                    45.8%                                           14                                                  82.4%           43       58.9%   4,825    42.4%    
  **Urban/rural**           Rural                    0                                  0                                      48                                              7.7%                                                0               0        6       8.2%     1,039    9.1%
  Urban                     29                       100%                               576                                    92.3%                                           17                                                  100%            67       91.8%   10,343   90.9%    
  **HSCT**                                                                                                                                                                                                                                                                            
  **Unique patients**                                109                                                                       7,513                                                                                               228                      1,634            4,736    
  **Unique providers**                               31                                                                        175                                                                                                 35                       71               382      
  **Age, years**            Minimum--maximum         1                                  85+                                    0                                               85+                                                 4               82       0       85       0        85+
  Mean                      53                                                          53                                                                                     52                                                                  43               51                
  SD                        ±16.48                                                      ±17.52                                                                                 ±15.63                                                              ±22.28           ±22.48            
  Median                    57                                                          58                                                                                     55                                                                  51               57                
  IQR                       46                       64                                 46                                     65                                              44.5                                                63              24       61      38       67       
  **Age-group, years**      0--17                    4                                  3.7%                                   470                                             6.3%                                                8               3.5%     326     20       687      14.5%
  18--34                    13                       11.9%                              617                                    8.2%                                            28                                                  12.3%           194      11.9%   404      8.5%     
  35--44                    8                        7.3%                               622                                    8.3%                                            21                                                  9.2%            153      9.4%    329      6.9%     
  45--64                    59                       54.1%                              3,711                                  49.4%                                           121                                                 53.1%           674      41.2%   1,864    39.4%    
  65--74                    19                       17.4%                              1,914                                  25.5%                                           46                                                  20.2%           269      16.5%   985      20.8%    
  75 +                      6                        5.5%                               179                                    2.4%                                            4                                                   1.8%            18       1.1%    467      9.9%     
  **Sex**                   Male                     63                                 57.8%                                  4,345                                           57.8%                                               138             60.5%    955     58.4%    2,604    55.0%
  Female                    46                       42.2%                              3,168                                  42.2%                                           90                                                  39.5%           679      41.6%   2,132    45.0%    
  Unknown                   0                        0                                  0                                      0                                               0                                                   0               0        0       0        0        
  **Race**                  White                    69                                 63.3%                                  5,359                                           71.3%                                               138             60.5%    1,034   63.3%    3,430    72.4%
  Black                     6                        5.5%                               873                                    11.6%                                           18                                                  7.9%            196      12.0%   539      11.4%    
  Other                     34                       31.2%                              1,281                                  17.1%                                           72                                                  31.6%           404      24.7%   767      16.2%    
  **Ethnicity**             Not Hispanic or Latino   70                                 64.2%                                  4,354                                           58.0%                                               118             51.8%    819     50.1%    3,288    69.4%
  Hispanic or Latino        10                       9.2%                               482                                    6.4%                                            14                                                  6.1%            111      6.8%    350      7.4%     
  Other                     29                       26.6%                              2,677                                  35.6%                                           96                                                  42.1%           704      43.1%   1,098    23.2%    
  **Admission type**        Urgent/emergent          43                                 39.5%                                  2,352                                           31.3%                                               82              35.9%    508     31.1%    2,158    45.5%
  Elective                  65                       59.6%                              5,117                                  68.1%                                           146                                                 64.0%           1,113    68.1%   2,551    53.9%    
  Trauma                    0                        0                                  2                                      0                                               0                                                   0               1        0.1%    1        0        
  Other/unknown             1                        0.9%                               42                                     0.6%                                            0                                                   0               12       0.7%    26       0.5%     
  **Discharge status**      Home                     107                                98.2%                                  7,197                                           95.8%                                               194             85.1%    1,388   84.9%    4,298    90.8%
  Transferred               1                        0.9%                               53                                     0.7%                                            4                                                   1.8%            32       2.0%    67       1.4%     
  SNF                       0                        0                                  92                                     1.2%                                            0                                                   0               27       1.7%    203      4.3%     
  Expired                   1                        0.9%                               62                                     0.8%                                            25                                                  11.0%           150      9.2%    80       1.7%     
  Hospice                   0                        0                                  17                                     0.2%                                            2                                                   0.9%            14       0.9%    58       1.2%     
  Other/unknown             0                        0                                  92                                     1.2%                                            3                                                   1.3%            23       1.4%    30       0.6%     
  **No. of beds**           1--149                   0                                  0                                      12                                              0.2%                                                0               0        0       0        90       1.9%
  150--249                  4                        3.7%                               833                                    11.1%                                           8                                                   3.5%            202      12.4%   530      11.2%    
  250--349                  4                        3.7%                               421                                    5.6%                                            9                                                   3.9%            65       4.0%    460      9.7%     
  350--449                  24                       22.0%                              477                                    6.3%                                            26                                                  11.4%           69       4.2%    703      14.8%    
  450--549                  5                        4.6%                               531                                    7.1%                                            8                                                   3.5%            134      8.2%    767      16.2%    
  550+                      72                       66.1%                              5,239                                  69.7%                                           177                                                 77.6%           1,164    71.2%   2,186    46.2%    
  **Geographic region**     West                     10                                 9.2%                                   687                                             9.1%                                                9               3.9%     70      4.3%     767      16.2%
  Midwest                   15                       13.7%                              1116                                   14.8%                                           24                                                  10.5%           271      16.6%   971      20.5%    
  Northeast                 31                       28.4%                              2,740                                  36.5%                                           93                                                  40.8%           630      38.6%   855      18.0%    
  South                     53                       48.7%                              2970                                   39.5%                                           102                                                 44.7%           663      40.6%   2,143    45.3%    
  **Teaching**              Yes                      28                                 25.7%                                  1,606                                           21.4%                                               24              10.5%    243     14.9%    1,832    38.7%
  No                        81                       74.3%                              5,907                                  78.6%                                           204                                                 89.5%           1,391    85.1%   2,904    61.3%    
  **Urban/rural**           Rural                    0                                  0                                      143                                             1.9%                                                0               0        6       0.4%     247      5.2%
  Urban                     109                      100.0%                             7,370                                  98.1%                                           228                                                 100.0%          1,628    99.6%   4,489    94.8%    
  **GVHD**                                                                                                                                                                                                                                                                            
  **Unique patients**                                225                                                                       2,192                                                                                               231                      769              2,014    
  **Unique providers**                               69                                                                        341                                                                                                 37                       102              495      
  **Age, years**            Minimum--maximum         0                                  74                                     0                                               85                                                  12              78       0       77       0        85+
  Mean                      51                                                          47                                                                                     50                                                                  42               49                
  SD                        ±14.53                                                      ±18.86                                                                                 ±15.13                                                              ±21.12           ±17.92            
  Median Age-group, years   55                                                          52                                                                                     53                                                                  48               53                
  IQR                       42                       62                                 36                                     61                                              42                                                  62              24       59      37       62       
  **Age-group, years**      0--17                    3                                  1.3%                                   230                                             10.5%                                               6               2.6%     143     18.6%    143      7.1%
  18--34                    39                       17.3%                              289                                    13.2%                                           38                                                  16.5%           124      16.1%   297      14.7%    
  35--44                    26                       11.6%                              250                                    11.4%                                           21                                                  9.1%            84       10.9%   245      12.2%    
  45--64                    120                      53.3%                              1,085                                  49.5%                                           125                                                 54.1%           320      41.6%   977      48.5%    
  65--74                    37                       16.4%                              323                                    14.7%                                           40                                                  17.3%           95       12.4%   298      14.8%    
  75+                       0                        0                                  15                                     0.7%                                            1                                                   0.4%            3        0.4%    54       2.7%     
  **Sex**                   Male                     144                                64.0%                                  1,268                                           57.8%                                               132             57.1%    451     58.6%    1,144    56.8%
  Female                    81                       36.0%                              924                                    42.2%                                           99                                                  42.9%           318      41.4%   870      43.2%    
  Unknown                   0                        0                                  0                                      0                                               0                                                   0               0        0       0        0        
  **Race**                  White                    181                                80.4%                                  1,668                                           76.1%                                               156             67.5%    554     72.0%    1,455    72.2%
  Black                     14                       6.2%                               146                                    6.7%                                            23                                                  10.0%           73       9.5%    202      10.0%    
  Other                     30                       13.3%                              378                                    17.2%                                           52                                                  22.5%           142      18.5%   357      17.7%    
  **Ethnicity**             Not Hispanic or Latino   157                                69.8%                                  1,295                                           59.1%                                               148             64.1%    449     58.4%    1,147    57.0%
  Hispanic or Latino        17                       7.6%                               126                                    5.7%                                            11                                                  4.8%            57       7.4%    119      5.9%     
  Other                     51                       22.7%                              771                                    35.2%                                           72                                                  31.2%           263      34.2%   748      37.1%    
  **Admission type**        Urgent/emergent          179                                79.6%                                  1,576                                           71.9%                                               140             60.6%    409     53.1%    1,596    79.2%
  Elective                  45                       20.0%                              593                                    27.1%                                           89                                                  38.5%           351      45.6%   382      19.0%    
  Trauma                    1                        0.4%                               5                                      0.2%                                            0                                                   0               1        0.1%    8        0.4%     
  Other/unknown             0                        0                                  18                                     0.8%                                            2                                                   0.9%            8        1.0%    28       1.4%     
  **Discharge status**      Home                     186                                82.7%                                  1,702                                           77.6%                                               160             69.3%    526     68.4%    1,518    75.4%
  Transferred               13                       5.8%                               201                                    9.2%                                            16                                                  6.9%            53       6.9%    199      9.9%     
  SNF                       9                        4.0%                               55                                     2.5%                                            6                                                   2.6%            16       2.1%    106      5.3%     
  Expired                   7                        3.1%                               130                                    5.9%                                            34                                                  14.7%           145      18.9%   89       4.4%     
  Hospice                   3                        1.3%                               39                                     1.8%                                            9                                                   3.9%            14       1.8%    30       1.5%     
  Other/unknown             7                        3.1%                               65                                     3.0%                                            6                                                   2.6%            15       2.0%    72       3.6%     
  **No. of beds**           1--149                   2                                  0.9%                                   57                                              2.6%                                                1               0.4%     4       0.5%     159      7.9%
  150--249                  10                       4.4%                               271                                    12.4%                                           9                                                   3.9%            150      19.5%   239      11.9%    
  250--349                  12                       5.3%                               218                                    9.9%                                            12                                                  5.2%            31       4.0%    331      16.4%    
  350--449                  19                       8.4%                               226                                    10.3%                                           9                                                   3.9%            44       5.7%    352      17.5%    
  450--549                  20                       8.9%                               165                                    7.5%                                            9                                                   3.9%            40       5.2%    247      12.3%    
  550+                      162                      72.0%                              1,255                                  57.3%                                           191                                                 82.7%           500      65.0%   686      34.1%    
  **Geographic region**     West                     26                                 11.5%                                  271                                             12.3%                                               7               3.0%     42      5.5%     432      21.4%
  Midwest                   24                       10.6%                              327                                    14.9%                                           12                                                  5.2%            114      14.9%   358      17.8%    
  Northeast                 94                       41.8%                              574                                    26.2%                                           118                                                 51.1%           268      34.8%   382      19.0%    
  South                     81                       36.0%                              1020                                   46.5%                                           94                                                  40.7%           345      44.9%   842      41.8%    
  **Teaching**              Yes                      42                                 18.7%                                  743                                             33.9%                                               16              6.9%     203     26.4%    929      46.1%
  No                        183                      81.3%                              1,449                                  66.1%                                           215                                                 93.1%           566      73.6%   1,085    53.9%    
  **Urban/rural**           Rural                    3                                  1.3%                                   76                                              3.5%                                                0               0        5       0.7%     148      7.3%
  Urban                     222                      98.7%                              2,116                                  96.5%                                           231                                                 100%            764      99.3%   1,866    92.7%    

**Note:** All values are presented as number and percentages unless otherwise designated.

**Abbreviations:** AML, acute myeloid leukemia; GVHD, graft-vs-host disease; HSCT, hematopoietic stem-cell transplantation; MDS, myelodysplastic syndrome; SNF, skilled nursing facility.
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![Inpatients receiving posaconazole by formulation and by year.\
**Notes:** Patients receiving varying formulations of posaconazole during the study years. This graph highlights the declining number of inpatients with posaconazole oral suspension after 2013, when the oral tablet formulation became available. The proportion of inpatients receiving the tablet formulation has increased rapidly in recent years, and parenteral posaconazole was found to have a very small uptake. A total of nine cases from 2014 to the first quarter of 2016 had unknown or unidentifiable formulations.](ceor-10-371Fig1){#f1-ceor-10-371}

![Inpatients with 90-day subsequent inpatient (**A**) and outpatient visits (**B**) with IFI by cohort and by year.\
**Notes:** There was no noticeable trend over time, and patients with 90-day IFI-related subsequent inpatient and outpatient visits appeared to be rare across the four study cohorts. No GVHD encounters in 2007 met the study-inclusion criteria; therefore, readmissions and outpatient visits were not presented for the GVHD cohort in 2007.\
**Abbreviations:** AML, acute myeloid leukemia; GVHD, graft-vs-host disease; HSCT, hematopoietic stem-cell transplantation; IFI, invasive fungal infection; MDS, myelodysplastic syndrome.](ceor-10-371Fig2){#f2-ceor-10-371}

###### 

Patient, visit, and hospital characteristics of patients with a diagnosis of AML, MDS, HSCT, or GVHD without documented fungal infections

                                                   AML               MDS               HSCT              GVHD    
  ----------------------- ------------------------ -------- -------- -------- -------- -------- -------- ------- -------
  **Unique patients**                              19,872            12,125            14,220            5,431   
  **Unique providers**                             736               753               391               553     
  **Age, years**          Minimum--maximum         0        85+      0        85+      0        85+      0       85+
  Mean                    64                                76                51                47               
  SD                      ±19.18                            ±12.75            ±20.06            ±18.71           
  Median                  68                                79                57                52               
  IQR                     54                       78       70       85       42       65       35       61      
  **Age-group, years**    0--17                    562      2.8%     46       0.4%     1,495    10.5%    525     9.7%
  18--34                  1,317                    6.6%     89       0.7%     1,256    8.8%     787      14.5%   
  35--44                  1,253                    6.3%     118      1.0%     1,133    8.0%     626      11.5%   
  45--64                  5,349                    26.9%    1,576    13.0%    6,429    45.2%    2,627    48.4%   
  65--74                  4,770                    24.0%    2,642    21.8%    3,233    22.7%    793      14.6%   
  75+                     6,621                    33.3%    7,654    63.1%    674      4.7%     73       1.3%    
  **Sex**                 Male                     10,922   55.0%    6,628    54.7%    8,105    57.0%    3,139   57.8%
  Female                  8,945                    45.0%    5,495    45.3%    6,115    43.0%    2,292    42.2%   
  Unknown                 5                        0.0%     2        0.0%     0        0.0%     0        0.0%    
  **Race**                White                    14,209   71.5%    8,938    73.7%    10,030   70.5%    4,014   73.9%
  Black                   1,917                    9.6%     1,121    9.2%     1,632    11.5%    458      8.4%    
  Other                   3,746                    18.9%    2,066    17.0%    2,558    18.0%    959      17.7%   
  **Ethnicity**           Not Hispanic or Latino   9,323    46.9%    5,805    47.9%    8,649    60.8%    3,196   58.8%
  Hispanic or Latino      1,234                    6.2%     662      5.5%     967      6.8%     330      6.1%    
  Other                   9,315                    46.9%    5,658    46.7%    4,604    32.4%    1,905    35.1%   
  **Admission type**      Urgent/emergent          16,765   84.4%    10,456   86.2%    5,143    36.2%    3,900   71.8%
  Elective                2,913                    14.7%    1,572    13.0%    8,992    63.2%    1,460    26.9%   
  Trauma                  52                       0.3%     23       0.2%     4        0.0%     15       0.3%    
  Other/Unknown           142                      0.7%     74       0.6%     81       0.6%     56       1.0%    
  **Discharge status**    Home                     10,211   51.4%    8,241    68.0%    13,184   92.7%    4,092   75.3%
  Transferred             2,487                    12.5%    335      2.8%     157      1.1%     482      8.9%    
  SNF                     877                      4.4%     2,075    17.1%    322      2.3%     192      3.5%    
  Expired                 3,234                    16.3%    541      4.5%     318      2.2%     405      7.5%    
  Hospice                 2,620                    13.2%    814      6.7%     91       0.6%     95       1.7%    
  Other/unknown           443                      2.2%     119      1.0%     148      1.0%     165      3.0%    
  **No. of beds**         1--149                   1,057    5.3%     1,087    9.0%     102      0.7%     223     4.1%
  150--249                2,366                    11.9%    1,942    16.0%    1,577    11.1%    679      12.5%   
  250--349                2,969                    14.9%    2,312    19.1%    959      6.7%     604      11.1%   
  350--449                3,372                    17.0%    2,213    18.3%    1,299    9.1%     650      12.0%   
  450--549                2,747                    13.8%    1,685    13.9%    1,445    10.2%    481      8.9%    
  550+                    7,361                    37.0%    2,886    23.8%    8,838    62.2%    2,794    51.4%   
  **Geographic region**   West                     3,288    16.6%    1,921    15.8%    1,543    10.8%    778     14.3%
  Midwest                 3,581                    18.0%    2280     18.8%    2397     16.9%    835      15.4%   
  Northeast               3,716                    18.7%    2,425    20.0%    4,349    30.5%    1,436    26.4%   
  South                   9,287                    46.7%    5499     45.4%    5931     41.7%    2382     43.8%   
  **Teaching**            Yes                      9,405    47.3%    6,937    57.2%    3,733    26.3%    1,933   35.6%
  No                      10,467                   52.7%    5,188    42.8%    10,487   73.7%    3,498    64.4%   
  **Urban/rural**         Rural                    1,350    6.8%     1,093    9.0%     396      2.8%     232     4.3%
  Urban                   18,522                   93.2%    11,032   91.0%    13,824   97.2%    5,199    95.7%   

**Note**: All values are presented as number and percentages unless otherwise designated.

**Abbreviations:** AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; HSCT, hematopoietic stem-cell transplantation; GVHD, graft-vs-host disease; SNF, skilled nursing facility.

###### 

Economic and clinical outcomes in AML patients without fungal infection diagnosis

                                                                                                                  Single antifungal (posaconazole)   Single antifungal (not posaconazole)   Multiple antifungals (including posaconazole)   Multiple antifungals (not including posaconazole)   No antifungal                                                            
  -------------------------------------------------------------------------------------------- ------------------ ---------------------------------- -------------------------------------- ----------------------------------------------- --------------------------------------------------- --------------- ------------- ------------- ------------- -------------- -----------
  **Unique patients**                                                                                             565                                                                       4,778                                                                                               812                           2,235                       11,482         
  **Unique providers**                                                                                            103                                                                       516                                                                                                 112                           309                         724            
  **Denominator for index LOS and total index hospital cost**                                                     **n=565**                                                                 **n=4,778**                                                                                         **n=812**                     **n=2,235**                 **n=11,482**   
  Index LOS                                                                                    Minimum--maximum   1                                  70                                     1                                               213                                                 2               162           1             280           1              189
  Mean                                                                                         24.79                                                 20.63                                                                                  35.22                                                               34.01                       7.02                         
  SD                                                                                           ±13.79                                                ±15.46                                                                                 ±18.39                                                              ±17.60                      ±8.56                        
  Median                                                                                       26                                                    21                                                                                     31                                                                  31                          4                            
  IQR                                                                                          14                 32                                 7                                      30                                              25                                                  42              25            41            2             8              
  Total index hospital cost, USD\$                                                             Minimum--maximum   1,499.51                           1,163,262                              398.02                                          880,313                                             1419.57         4,535,851     3,225.15      964,870.3     1.09           977,379.8
  Mean                                                                                         61,206.88                                             49,435.92                                                                              99,937.16                                                           89,630.58                   16,559.98                    
  SD                                                                                           ±60,905.37                                            ±45,897.58                                                                             ±17,4345.8                                                          ±64,621.83                  ±24,928.34                   
  Median                                                                                       56,993.39                                             41,806.57                                                                              76,766.25                                                           75,379.69                   8,989.77                     
  IQR                                                                                          33,494.43          78,162.05                          16,772.19                              67,282.66                                       54,409.96                                           108,712.6       53,806.16     108,052.5     4,911.21      17,461.34      
  **Denominator for readmissions and subsequent visits (excludes death during index visit)**   **n=514**                                             **n=4,087**                                                                            **n=693**                                                           **n=1,823**                 **n=9,521**                  
  30-Day readmission with IFIs                                                                 3                  0.6%                               79                                     1.9%                                            10                                                  1.4%            48            2.6%          88            0.9%           
  30-Day outpatient visit with IFIs                                                            0                  0                                  1                                      0                                               1                                                   0.1%            2             0.1%          5             0.1%           
  60-Day readmission with IFIs                                                                 6                  1.2%                               117                                    2.9%                                            13                                                  1.9%            84            4.6%          128           1.3%           
  60-Day outpatient visit with IFIs                                                            0                  0                                  6                                      0.1%                                            1                                                   0.1%            6             0.3%          14            0.1%           
  90-Day readmission with IFIs                                                                 12                 2.3%                               153                                    3.7%                                            16                                                  2.3%            109           6.0%          159           1.7%           
  90-Day outpatient visit with IFIs                                                            0                  0                                  7                                      0.2%                                            2                                                   0.3%            9             0.5%          18            0.2%           

**Note:** All values are presented as number and percentages unless otherwise designated.

**Abbreviations:** AML, acute myeloid leukemia; LOS, length of stay; IFIs, invasive fungal infections.

###### 

Economic and clinical outcomes in MDS patients without fungal infection diagnosis

                                                                                               Single antifungal (posaconazole)   Single antifungal (not posaconazole)   Multiple antifungals (including posaconazole)   Multiple antifungals (not including posaconazole)   No antifungal                                                                   
  -------------------------------------------------------------------------------------------- ---------------------------------- -------------------------------------- ----------------------------------------------- --------------------------------------------------- --------------- ----------- ------------ ----------- -------------- ----------- -----------
  **Unique patients**                                                                          29                                                                        624                                                                                                 17                          73                       11,382                     
  **Unique providers**                                                                                                            19                                                                                     300                                                                 10                       56                         748         
  **Denominator for index LOS and total index hospital cost**                                  **n=29**                                                                  **n=624**                                                                                           **n=17**                    **n=73**                 **n=11,382**               
  Index LOS                                                                                    Minimum-maximum                    3                                      51                                              1                                                   74              4           70           1           88             1           71
                                                                                               Mean                               1 1.59                                                                                 10.07                                                               31.59                    20.97                      4.76        
                                                                                               SD                                 ±11.36                                                                                 ±9.67                                                               ±18.57                   ±17.94                     ±4.54       
                                                                                               Median                             7                                                                                      7                                                                   26                       16                         3           
                                                                                               IQR                                4                                      12                                              4                                                   14              22          38           10          23             2           6
  Total index hospital cost, USD\$                                                             Minimum-maximum                    4,988.19                               12,4338.3                                       613.72                                              311,336.4       15,860.76   321,775.3    5,540.52    443,352.4      6.24        223,411.4
  Mean                                                                                         29,465.95                                                                 23,930.41                                                                                           92,101.74                   63,885.38                9,482.05                   
  SD                                                                                           ±28,193.38                                                                ±29,1 16.92                                                                                         ±85,1 12.77                 ±78,483.42               ±10,584.59                 
  Median                                                                                       16,912.13                                                                 14,973.61                                                                                           61,276.62                   38,536.14                65,40.84                   
  IQR                                                                                          12,977.8                           30,012.21                              7,238.77                                        29,733.78                                           37,403.97       110,684.9   19,868.83    76,730.25   3,804.16       11,252.56   
  **Denominator for readmissions and subsequent visits (excludes death during index visit)**   **n=27**                                                                  **n=560**                                                                                           **n=17**                    **n=55**                 **n=10,925**               
  30-Day readmission with 1 FIs                                                                0                                  0                                      4                                               0.7%                                                2               1 1.8%      2            3.6%        56             0.5%        
  30-Day outpatient visit with IFIs                                                            0                                  0                                      0                                               0                                                   0               0           0            0           7              0.1%        
  60-Day readmission with IFIs                                                                 0                                  0                                      10                                              1.8%                                                2               11.8%       2            3.6%        96             0.9%        
  60-Day outpatient visit with IFIs                                                            0                                  0                                      0                                               0                                                   0               0           0            0           12             0.1%        
  90-Day readmission with IFIs                                                                 0                                  0                                      12                                              2.1%                                                2               11.8%       2            3.6%        128            1.2%        
  90-Day outpatient visit with IFIs                                                            0                                  0                                      0                                               0                                                   0               0           0            0           13             0.1%        

**Note:** All values are presented as number and percentages unless otherwise designated.

**Abbreviations:** MDS, myelodysplastic syndrome; LOS, length of stay; IFIs, invasive fungal infections.

###### 

Economic and clinical outcomes in HSCT patients without fungal infection diagnosis

                                                                                                                 Single antifungal (posaconazole)   Single antifungal (not posaconazole)   Multiple antifungals (including posaconazole)   Multiple antifungals (not including posaconazole)   No antifungal                                                        
  -------------------------------------------------------------------------------------------- ----------------- ---------------------------------- -------------------------------------- ----------------------------------------------- --------------------------------------------------- --------------- -------------- ----------- ------------- ----------- -----------
  **Unique patients**                                                                          109                                                  7,513                                                                                  228                                                                 1,634                      4,736                     
  **Unique providers**                                                                         31                                                   175                                                                                    35                                                                  71                         382                       
  **Denominator for index LOS and total index hospital cost**                                  **n=l 09**                                           **n=7,51 3**                                                                           **n=228**                                                           **n=1,634**                **n=4,736**               
  Index LOS                                                                                    Minimum-maximum   2                                  60                                     1                                               203                                                 2               122            5           309           1           121
  Mean                                                                                         20.04                                                18.83                                                                                  36.16                                                               34.63                      7.1 1                     
  SD                                                                                           ±10.38                                               ±9.94                                                                                  ±20.79                                                              ±22.12                     ±7.64                     
  Median                                                                                       20                                                   18                                                                                     29.5                                                                28                         4                         
  IQR                                                                                          16                26                                 14                                     22                                              23                                                  42              23             38          3             8           
  Total index hospital cost, USD\$                                                             Minimum-maximum   4,734.8                            317,707.6                              254.08                                          3,406,753                                           7,147.45        584,183.1      13,850.58   1,839,1 13    37.71       392,230.4
  Mean                                                                                         68,409.84                                            66,626.48                                                                              145,063.6                                                           152,320.4                  21,950.22                 
  SD                                                                                           ±61,169.44                                           ±70,213.10                                                                             ±107,954.7                                                          ±130,782.9                 ±31,840.89                
  Median                                                                                       55,097.42                                            49,135.52                                                                              110,882.4                                                           117,352                    11,553.08                 
  IQR                                                                                          35,831.58         80,799.15                          35,054.09                              77,012.63                                       65,179.02                                           192,504.7       69,234.34      194,578.4   6,542.26      21,294.55   
  **Denominator for readmissions and subsequent visits (excludes death during index visit)**   **n=108**                                            **n=7,451**                                                                            **n=203**                                                           **n= 1,484**               **n=4,656**               
  30-Day readmission with IFIs                                                                 2                 1.9%                               38                                     0.5%                                            5                                                   2.5%            26             1.8%        50            1.1%        
  30-Day outpatient visit with IFIs                                                            0                 0                                  6                                      0.1%                                            1                                                   0.5%            3              0.2%        6             0.1%        
  60-Day readmission with IFIs                                                                 4                 3.7%                               63                                     0.8%                                            8                                                   3.9%            33             2.2%        75            1.6%        
  60-Day outpatient visit with IFIs                                                            0                 0                                  9                                      0.1%                                            1                                                   0.5%            5              0.3%        17            0.4%        
  90-Day readmission with IFIs                                                                 4                 3.7%                               77                                     1.0%                                            8                                                   3.9%            38             2.6%        100           2.1%        
  90-Day outpatient visit with IFIs                                                            1                 0.9%                               15                                     0.2%                                            1                                                   0.5%            6              0.4%        21            0.5%        

**Note:** All values are presented as number and percentages unless otherwise designated.

**Abbreviations:** HSCT, hematopoietic stem-cell transplantation; LOS, length of stay; IFIs, invasive fungal infections.

###### 

Economic and clinical outcomes in GVHD patients without fungal infection diagnosis

                                                                                                                 Single antifungal (posaconazole)   Single antifungal (not posaconazole)   Multiple antifungals (including posaconazole)   Multiple antifungals (not including posaconazole)   No antifungal                                                      
  -------------------------------------------------------------------------------------------- ----------------- ---------------------------------- -------------------------------------- ----------------------------------------------- --------------------------------------------------- --------------- ------------ ----------- ------------- ----------- -----------
  **Unique patients**                                                                                            225                                                                       2,192                                                                                               231                          769                       2,014       
  **Unique providers**                                                                                           69                                                                        341                                                                                                 37                           102                       495         
  **Denominator for index LOS and total index hospital cost**                                  **n=225**                                            **n=2,192**                                                                            **n=231**                                                           **n=769**                **n=2,014**               
  Index LOS                                                                                    Minimum-maximum   1                                  55                                     1                                               196                                                 3               184          1           255           1           197
  Mean                                                                                         9.4                                                  1 1.97                                                                                 35.44                                                               37.07                    6.28                      
  SD                                                                                           ±10.76                                               ±16.14                                                                                 ±28.67                                                              ±31.53                   ±9.20                     
  Median                                                                                       5                                                    6                                                                                      29                                                                  31                       4                         
  IQR                                                                                          3                 1 1                                3                                      15                                              19                                                  46              16           47          2             7           
  Total index hospital cost, USD\$                                                             Minimum-maximum   1,157.65                           288,145                                924.71                                          1,691,789                                           5,416.78        767,010.5    2,235.59    2,154,246     95.79       675,867.5
  Mean                                                                                         28,524.02                                            42,722.97                                                                              137,906.8                                                           171,763.4                17,449.48                 
  SD                                                                                           ±42,295.20                                           ±81,534.22                                                                             ±138,165.2                                                          ±189,478.3               ±40,378.73                
  Median                                                                                       12,373.78                                            14,671.42                                                                              96,129.21                                                           125,417                  8,489.03                  
  IQR                                                                                          7,400.29          31,269.96                          7,151.84                               42,652.34                                       47,203.79                                           178,955.9       45,862.75    220,542.7   4,529.42      16,350.46   
  **Denominator for réadmissions and subsequent visits (excludes death during index visit)**   **n=218**                                            **n=2,062**                                                                            **n=197**                                                           **n=624**                **n=1,925**               
  30-Day readmission with IFIs                                                                 4                 1.8%                               32                                     1.6%                                            4                                                   2.0%            24           3.8%        12            0.6%        
  30-Day outpatient visit with IFIs                                                            1                 0.5%                               5                                      0.2%                                            2                                                   1.0%            3            0.5%        2             0.1%        
  60-Day readmission with IFIs                                                                 8                 3.7%                               51                                     2.5%                                            7                                                   3.6%            32           5.1%        23            1.2%        
  60-Day outpatient visit with IFIs                                                            1                 0.5%                               8                                      0.4%                                            2                                                   1.0%            4            0.6%        4             0.2%        
  90-Day readmission with IFIs                                                                 10                4.6%                               65                                     3.2%                                            8                                                   4.1%            38           6.1%        30            1.6%        
  90-Day outpatient visit with IFIs                                                            1                 0.5%                               10                                     0.5%                                            3                                                   1.5%            5            0.8%        7             0.4%        

**Note:** All values are presented as number and percentages unless otherwise designated.

**Abbreviations:** GVHD, graft-vs-host disease; LOS, length of stay; IFIs, invasive fungal infections.
